1-7 of 7
Pang-Dian Fan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 1088: An evaluation of patritumab deruxtecan (HER3-DXd, U3-1402) against pediatric PDX models for hepatoblastoma and rhabdomyosarcoma - A report from the NCI PIVOT Program

Raushan Kurmasheva, Peter Houghton, Vanessa Del Pozo, Samson Ghilu, Ryuichi Nakamura, Pang-Dian Fan, Emily Jocoy, Tim Stearns, Steve Neuhauser, Jeff Chuang, Carol J. Bult, Beverly A. Teicher, Malcolm A. Smith
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 1088.
https://doi.org/10.1158/1538-7445.AM2024-1088
Published: 22 March 2024
View article titled, Abstract 1088: An evaluation of patritumab deruxtecan (HER3-DXd, U3-1402) against pediatric PDX models for hepatoblastoma and rhabdomyosarcoma - A report from the NCI PIVOT Program
Journal Articles

Abstract LB042: Targeting ATR enhances the antitumor efficacy of patritumab deruxtecan (HER3-DXd)in tamoxifen-resistant ER+ breast cancer cells by inducing DNA damage and apoptosis

Xuemei Xie, Jangsoon Lee, Jon A. Fuson, Huey Liu, Young J. Gi, Thanasis Poullikkas, Pang-Dian Fan, Kumiko Koyama, Debu Tripathy, Naoto T. Ueno
Journal: Cancer Research
Cancer Res (2023) 83 (8_Supplement): LB042.
https://doi.org/10.1158/1538-7445.AM2023-LB042
Published: 14 April 2023
View article titled, Abstract LB042: Targeting ATR enhances the antitumor efficacy of patritumab deruxtecan (HER3-DXd)in tamoxifen-resistant ER<sup>+</sup> breast cancer cells by inducing DNA damage and apoptosis
Journal Articles

Abstract P5-02-31: Genetic determinants of response to patritumab deruxtecan (HER3-DXd) in hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer: a correlative analysis from SOLTI TOT-HER3 trial

Fara Brasó-Maristany, Claudette Falato, Olga Martínez-Sáez, Juan Miguel Cejalvo, Mireia Margelí, Pablo Tolosa, Francisco Javier Salvador Bofill, Josefina Cruz, Blanca González-Farré, Esther Sanfeliu, Míriam Arumí, Guillermo Villacampa, Eva Ciruelos, Martín Espinosa-Bravo, Yann Izarzuzaga, Patricia Galván, Judit Matito, Sonia Pernas, Anu Santhanagopal, Stephen Esker, Parul Patel, Pang-Dian Fan, Juan Manuel Ferrero-Cafiero, Ana Vivancos, Tomás Pascual, Aleix Prat, Mafalda Oliveira
Journal: Cancer Research
Cancer Res (2023) 83 (5_Supplement): P5-02-31.
https://doi.org/10.1158/1538-7445.SABCS22-P5-02-31
Published: 01 March 2023
View article titled, Abstract P5-02-31: Genetic determinants of response to patritumab deruxtecan (HER3-DXd) in hormone receptor-positive/HER2-negative (HR+/HER2-) breast cancer: a correlative analysis from SOLTI TOT-HER3 trial
Journal Articles

Abstract LB088: Targeting ATR enhances the antitumor efficacy of patritumab deruxtecan (HER3-DXd) in tamoxifen-resistant ER+ breast cancer cells by reprogramming cell cycle progression

Xuemei Xie, Jangsoon Lee, Jon A. Fuson, Huey Liu, Young Jin Gi, Pang-Dian Fan, Kumiko Koyama, Debu Tripathy, Naoto T. Ueno
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): LB088.
https://doi.org/10.1158/1538-7445.AM2022-LB088
Published: 15 June 2022
View article titled, Abstract LB088: Targeting ATR enhances the antitumor efficacy of patritumab deruxtecan (HER3-DXd) in tamoxifen-resistant ER<sup>+</sup> breast cancer cells by reprogramming cell cycle progression
Journal Articles

Abstract PD13-04: Activity of patritumab deruxtecan, a HER3-directed antibody drug conjugate, in early breast cancer according to ERBB3 expression: Interim analysis results of a window-of-opportunity study (SOLTI-1805 TOT-HER3)

Aleix Prat, Juan M. Cejalvo, Laia Pare, Olga Martínez-Sáez, Mireia Margelí Vila, Claudette Falato, Josefina Cruz, Miriam Arumí de Dios, Maria J Vidal, Juan Antonio Guerra, Ana Maria Luna Barrera, Pablo Tolosa, Francisco Javier Salvador-Bofill, Sonia Pernas, Blanca Gonzáles-Farré, Esther Sanfeliu, Eva Ciruelos, Violeta Serra, Martin Espinosa-Bravo, Yann Izarzugaza, Stephen Esker, Pang-Dian Fan, Guillermo Villacampa, Juan M Ferrero-Cafiero, Tomás Pascual, Mafalda Oliveira
Journal: Cancer Research
Cancer Res (2022) 82 (4_Supplement): PD13-04.
https://doi.org/10.1158/1538-7445.SABCS21-PD13-04
Published: 15 February 2022
View article titled, Abstract PD13-04: Activity of patritumab deruxtecan, a HER3-directed antibody drug conjugate, in early breast cancer according to ERBB3 expression: Interim analysis results of a window-of-opportunity study (SOLTI-1805 TOT-HER3)
Journal Articles

ERBB3-Independent Activation of the PI3K Pathway in EGFR-Mutant Lung Adenocarcinomas

Xiaoling Song, Pang-Dian Fan, Amlak Bantikassegn, Udayan Guha, David W. Threadgill, Harold Varmus, Katerina Politi
Journal: Cancer Research
Series: Author Choice
Cancer Res (2015) 75 (6): 1035–1045.
https://doi.org/10.1158/0008-5472.CAN-13-1625
Published: 12 March 2015
View article titled, ERBB3-Independent Activation of the PI3K Pathway in EGFR-Mutant Lung Adenocarcinomas
Open the PDF for ERBB3-Independent Activation of the PI3K Pathway in EGFR-Mutant Lung Adenocarcinomas in another window
Includes: Supplementary data
Journal Articles

Homo- and Hetero-Oligomerization of the c-Abl Kinase and Abelson-Interactor-1

Pang-Dian Fan, Feng Cong, Stephen P. Goff
Journal: Cancer Research
Cancer Res (2003) 63 (4): 873–877.
Published: 15 February 2003
View article titled, Homo- and Hetero-Oligomerization of the c-Abl Kinase and Abelson-Interactor-1
Open the PDF for Homo- and Hetero-Oligomerization of the c-Abl Kinase and Abelson-Interactor-1 in another window